Shingles Vaccine’s Hidden Heart Edge

A vaccine most people get to dodge a painful rash may also be quietly guarding their heart.

Quick Take

A large study found Shingrix, the modern shingles vaccine, was tied to a 9% drop in cardiovascular problems over seven years compared to the older shot, Zostavax.
Researchers saw the biggest gains against ischemic heart disease and heart failure, with reductions of 10% and 12%.
Separate studies and meta-analyses, some showing risk drops as high as 23%, back up the same basic pattern.
Doctors say the shots are not causing the drop directly, but the vaccine may calm inflammation that fuels heart disease.

What The New Research Actually Found

A peer-reviewed 2026 study tracked people who got either Shingrix or the discontinued Zostavax vaccine. Researchers found the recombinant vaccine, Shingrix, was linked to a 9% decrease in cardiovascular burden over seven years. That number breaks down further into a 10% cut in ischemic heart disease and a 12% cut in heart failure cases.

Bloomberg reported the comparison came from patients who got Shingrix living about 9% longer without cardiovascular disease than those who got the older Merck vaccine, Zostavax. That is not a small effect for a shot most adults already get to avoid shingles, a painful skin condition caused by the chickenpox virus reactivating later in life.

Other Studies Point The Same Direction

This is not a lone finding. A systematic review and meta-analysis found shingles vaccination, using either the newer or older shot, was linked to an 18% drop in cardiovascular events for adults 18 and older, and 16% for those 50 and older. Another study of more than a million people found a 23% lower risk of cardiovascular events among the vaccinated, including a 26% drop in major events like stroke and heart attack.

A study presented at the American College of Cardiology found people with existing heart disease who got a shingles vaccine had nearly half the rate of serious cardiac events a year later, compared to those who skipped it. Reuters reported a separate analysis found Shingrix alone tied to a 21% lower risk of heart attack or stroke, translating to roughly 1.2 to 2.2 fewer major heart events per thousand people each year.

Why A Rash Vaccine Might Help The Heart

The shingles virus, herpes zoster, does more than cause a rash. It can trigger inflammation in blood vessels, and inflammation is a known driver of heart attacks and strokes. Researchers writing in Nature suggest the vaccine may work by preventing that viral flare-up in the first place, cutting off one pathway to vascular damage before it starts.

The Harvard Health Letter noted people who got the shot had about a 25% lower risk of various types of heart disease, including heart failure, angina, and irregular heartbeats, over six years. That is a wide net of benefits for a vaccine originally approved for a completely different reason.

Not Every Number Lines Up Perfectly

The size of the benefit varies across studies, from single-digit percentage drops to numbers approaching 25%. That range reflects differences in study design, populations, and follow-up time, not a contradiction in the core finding. Nearly every study reviewed points the same direction: fewer heart attacks, strokes, and heart failure cases among the vaccinated.

One study focused on patients with inflammatory arthritis found no significantly increased cardiovascular risk tied to Shingrix, aside from a temporary rise in blood clot risk right after a shingles infection itself. That detail matters because it shows the vaccine’s heart benefit shows up even in patients managing other serious health conditions.

Sources and notes:

The heart study: Corsi-Zuelli et al., Nature Medicine, Aug 26 2026. US TriNetX records, 70,000+ matched adults 60+, Shingrix vs the older Zostavax, 7-year follow-up. Overall cardiovascular burden 9% lower (RMTL ratio 0.91, CI 0.88 to 0.95), ischemic heart…

— Avi Roy (@agingroy) September 3, 2026

What This Means For Adults Weighing The Shot

Health officials already recommend Shingrix for adults 50 and older, and for younger adults with weakened immune systems. This growing body of research gives doctors another reason to bring it up during checkups, especially for patients already worried about heart disease. Cardiology groups are now treating shingles vaccination as a subject worth discussing during heart care, not just during routine vaccine visits.

None of this replaces proven heart care like managing blood pressure, cholesterol, or weight. But for a shot many adults already need, the mounting evidence suggests it may be doing more good than anyone expected when it first hit pharmacy shelves.